Yanfei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanfei Wang has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Ping Huang
Department of Cardiology
4 shared publications - Li Zhang
Department of Cardiology
3 shared publications - Hong-Ling Jia
Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, Guangdong, China
2 shared publications - Jiayong Zhong
Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University, Shenzhen, China
2 shared publications Wei Li
Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China
2 shared publications- Wei Li
Department of Cardiology
2 shared publications
Latest Publications
- 26 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158489
Discovery and characterization of hinokiflavone as a potent natural CD137 inhibitor for Kawasaki disease
- 26 June 2026
- Published by Elsevier in Phytomedicine
- Vol. 159, 158489
Discovery and characterization of hinokiflavone as a potent natural CD137 inhibitor for Kawasaki disease
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- 29 December 2025
- Published by Wiley in The FASEB Journal
- Vol. 40 (1) , e71378
Spatial Metabolomics Reveals GLA ‐Mediated Imbalance of Gal 2 Cer / GalCer as a Therapeutic Target in Myocardial Ischemia–Reperfusion Injury
Myocardial ischemia–reperfusion (I/R) injury, a major complication of reperfusion therapies for acute myocardial infarction that exacerbates myocardial necrosis, impairs cardiac function, and worsens patient prognosis. Profound metabolic disturbances drive myocardial I/R injury; however, their spatial heterogeneity remains unclear. Using MALDI mass spectrometry imaging with spatial segmentation, we mapped the spatiotemporal metabolite dynamics in mouse heart tissue across multiple time points (30 min ischemia to 7 days reperfusion), aiming to identify critical metabolic pathways and regulatory targets underlying I/R injury. Glycerophospholipids and sphingolipids exhibited pronounced heterogeneity. Glycerophospholipid metabolism remained dysregulated throughout the I/R process, with long‐chain phospholipids (PA, PE, PC, and PS) exhibiting a distinct distribution gradient. They were enriched in the remote zone, downregulated in the border zone, and markedly reduced in the injured zone 6 h post‐reperfusion. Sphingolipid metabolism was dynamically reprogrammed, with galactosylceramide (GalCer) accumulating and digalactosylceramide (Gal 2 Cer) depleting in injured and border zones. Mechanistically, α‐galactosidase (GLA), which hydrolyzes Gal2Cer to GalCer, was upregulated in the border zone post‐I/R. Functional validation further demonstrated that both cardiomyocyte‐specific GLA knockdown (via AAV‐shGla) and pharmacological inhibition (using the GLA inhibitor GR181413A) effectively reduced myocardial infarct size, alleviated pathological remodeling, and improved cardiac function in I/R‐injured mice. Collectively, our spatial metabolomics revealed that GLA‐mediated Gal2Cer/GalCer imbalance is a critical regulator of myocardial I/R injury, and targeting GLA represents a promising therapeutic strategy.
- Open Access
- 1 September 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (9) , 1854-1862
Identification of clinical risk factors for coronary artery lesions in children with Kawasaki disease: a retrospective cohort study
Background: Coronary artery lesions are the most severe complications of Kawasaki disease. Despite recent advances, evidence of the association between risk factors and coronary artery lesion is lacking. In this study, we demonstrated the potential clinical indicators that could assist to evaluate the prevalence of coronary artery lesion among paediatric patients with Kawasaki disease.Methods: We retrospectively enrolled 260 paediatric patients with Kawasaki disease. Patients with coronary dilation, coronary aneurysm, and intimal thickening of coronary arteries were included in this study. Medical records of each patient were collected. Logistic regression analysis was performed to explore risk factors and the occurrence of coronary artery lesion in patients with Kawasaki disease.Results: Respectively, 64 (24.6%), 39 (15%), and 56 patients (21.5%) of the participants had coronary dilation, coronary aneurysm, and intimal thickening of coronary arteries. Univariate analysis revealed that age, gender, duration of fever, time of initial use of intravenous immunoglobulin, erythrocyte sedimentation rate, white blood cell counts, time of platelet increase, the maximum value of platelet, albumin, and immunoglobulin G level was associated with coronary artery lesion. In multivariable logistic analysis, those younger and mainly males were associated with all three outcomes of coronary artery lesion, lower serum albumin levels, and later initial use of intravenous immunoglobulin were linked to a higher risk of coronary dilation and coronary aneurysm.Conclusions: The potential risk factors that could be used to estimate the occurrence of coronary artery lesion in Kawasaki disease patients are young age, male, lower serum albumin lever, and later initial use of intravenous immunoglobulin. However, long-term follow-up and multi-centre studies are required to verify our findings in the future.
- 1 September 2024
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (9) , 1854-1862
Open AccessIdentification of clinical risk factors for coronary artery lesions in children with Kawasaki disease: a retrospective cohort study
Background: Coronary artery lesions are the most severe complications of Kawasaki disease. Despite recent advances, evidence of the association between risk factors and coronary artery lesion is lacking. In this study, we demonstrated the potential clinical indicators that could assist to evaluate the prevalence of coronary artery lesion among paediatric patients with Kawasaki disease.Methods: We retrospectively enrolled 260 paediatric patients with Kawasaki disease. Patients with coronary dilation, coronary aneurysm, and intimal thickening of coronary arteries were included in this study. Medical records of each patient were collected. Logistic regression analysis was performed to explore risk factors and the occurrence of coronary artery lesion in patients with Kawasaki disease.Results: Respectively, 64 (24.6%), 39 (15%), and 56 patients (21.5%) of the participants had coronary dilation, coronary aneurysm, and intimal thickening of coronary arteries. Univariate analysis revealed that age, gender, duration of fever, time of initial use of intravenous immunoglobulin, erythrocyte sedimentation rate, white blood cell counts, time of platelet increase, the maximum value of platelet, albumin, and immunoglobulin G level was associated with coronary artery lesion. In multivariable logistic analysis, those younger and mainly males were associated with all three outcomes of coronary artery lesion, lower serum albumin levels, and later initial use of intravenous immunoglobulin were linked to a higher risk of coronary dilation and coronary aneurysm.Conclusions: The potential risk factors that could be used to estimate the occurrence of coronary artery lesion in Kawasaki disease patients are young age, male, lower serum albumin lever, and later initial use of intravenous immunoglobulin. However, long-term follow-up and multi-centre studies are required to verify our findings in the future.
- Open Access
- 3 August 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 2726686
Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
Background. Between 10 and 20% of Kawasaki disease (KD) patients are resistant to treatment with initial intravenous immunoglobulin (IVIG) and have a high risk of developing coronary artery lesions. Some studies have been conducted to identify predictive factors. However, the results are controversial. This study aims to identify the risk factors for IVIG‐resistant KD patients in a Chinese population. Methods. We performed a retrospective analysis of medical records of consecutive KD patients from two medical centers in South China from January 2015 to December 2017. A total of 1281 KD patients were eligible for inclusion in this study and maintained follow‐up for over 12 months. The KD patients were divided into two groups based on IVIG response. Clinical characteristics and laboratory variables were compared between the two groups. Multivariate logistic regression analysis was performed to identify the risk factors of IVIG resistance in KD patients. Results. Of the 1281 KD patients, 141 (11.0%) cases who were IVIG resistant to adjunctive therapies for primary treatment were classified as group 1. The remaining patients were in group 2 (n = 1140), classified as the control group. There was a significant difference in male to female ratio and the length of hospital stay between the two groups (P < 0.05). Group 1 had a higher white blood cell count (P = 0.01) and C‐reactive protein level (P < 0.01) before IVIG treatment than in group 2. Group 1 had a significantly higher white blood cell count and percentage of neutrophils after the IVIG infusion than in group 2 (P < 0.001). In addition, the mean values of C‐reactive protein level and neutrophil percentage before and after treatment difference comparison were significantly different. Multivariate analysis showed that patients presenting with coronary artery lesions in the acute phase and a C‐reactive protein level >100 mg/L at diagnosis were associated with IVIG resistance in KD. During the 12‐month follow‐up period, group 1 had an obviously higher incidence of coronary artery lesions than group 2, and the difference between the groups was statistically significant (P < 0.001). Conclusions. Patients presenting with coronary artery lesions in the acute phase and elevated C‐reactive protein levels before IVIG treatment might be a useful and important value for predicting IVIG resistance in KD. Risk assessment based on coronary artery lesions and C‐reactive protein levels prior to the treatment may improve the outcome of IVIG resistance.
- 3 August 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 2726686
Open AccessPredictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
Background. Between 10 and 20% of Kawasaki disease (KD) patients are resistant to treatment with initial intravenous immunoglobulin (IVIG) and have a high risk of developing coronary artery lesions. Some studies have been conducted to identify predictive factors. However, the results are controversial. This study aims to identify the risk factors for IVIG‐resistant KD patients in a Chinese population. Methods. We performed a retrospective analysis of medical records of consecutive KD patients from two medical centers in South China from January 2015 to December 2017. A total of 1281 KD patients were eligible for inclusion in this study and maintained follow‐up for over 12 months. The KD patients were divided into two groups based on IVIG response. Clinical characteristics and laboratory variables were compared between the two groups. Multivariate logistic regression analysis was performed to identify the risk factors of IVIG resistance in KD patients. Results. Of the 1281 KD patients, 141 (11.0%) cases who were IVIG resistant to adjunctive therapies for primary treatment were classified as group 1. The remaining patients were in group 2 (n = 1140), classified as the control group. There was a significant difference in male to female ratio and the length of hospital stay between the two groups (P < 0.05). Group 1 had a higher white blood cell count (P = 0.01) and C‐reactive protein level (P < 0.01) before IVIG treatment than in group 2. Group 1 had a significantly higher white blood cell count and percentage of neutrophils after the IVIG infusion than in group 2 (P < 0.001). In addition, the mean values of C‐reactive protein level and neutrophil percentage before and after treatment difference comparison were significantly different. Multivariate analysis showed that patients presenting with coronary artery lesions in the acute phase and a C‐reactive protein level >100 mg/L at diagnosis were associated with IVIG resistance in KD. During the 12‐month follow‐up period, group 1 had an obviously higher incidence of coronary artery lesions than group 2, and the difference between the groups was statistically significant (P < 0.001). Conclusions. Patients presenting with coronary artery lesions in the acute phase and elevated C‐reactive protein levels before IVIG treatment might be a useful and important value for predicting IVIG resistance in KD. Risk assessment based on coronary artery lesions and C‐reactive protein levels prior to the treatment may improve the outcome of IVIG resistance.
- Open Access
- 24 November 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020, 1-7
Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
There have been no robust data from clinical trials to guide the clinician in the choice of therapeutic agents for the child with intravenous immunoglobulin (IVIG) resistance. The treatment regimen for IVIG-resistant patients varies between institutions, and the best option has not yet been established. Therefore, in this trial, a total of 955 patients with Kawasaki disease (KD) were selected and were initially treated with IVIG (2 g/kg), of whom 80 (8.38%) assessed as IVIG resistant were randomly divided into two groups: Group A received the second IVIG treatment ( ), and Group B received methylprednisolone pulse therapy (MPT, ). The whole fever time, duration of fever after retreatment, hospital days, medical costs, readmission rate, and laboratory examination difference (△) were calculated. Coronary artery lesion (CAL) outcomes were followed up over two years. Patients in the MPT group had shorter fever after retreatment and lower medical costs; more rapid declines in C-reactive protein (CRP), neutrophils (N%), and platelet (PLT) levels; and more rapid rise in sodium. However, they also probably had a higher incidence of treatment failure and CALs than the additional IVIG treatment group in the long-term follow-up. Caution is still required in the use of MPT to treat IVIG-resistant KD.
- 24 November 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020, 1-7
Open AccessMethylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
There have been no robust data from clinical trials to guide the clinician in the choice of therapeutic agents for the child with intravenous immunoglobulin (IVIG) resistance. The treatment regimen for IVIG-resistant patients varies between institutions, and the best option has not yet been established. Therefore, in this trial, a total of 955 patients with Kawasaki disease (KD) were selected and were initially treated with IVIG (2 g/kg), of whom 80 (8.38%) assessed as IVIG resistant were randomly divided into two groups: Group A received the second IVIG treatment ( ), and Group B received methylprednisolone pulse therapy (MPT, ). The whole fever time, duration of fever after retreatment, hospital days, medical costs, readmission rate, and laboratory examination difference (△) were calculated. Coronary artery lesion (CAL) outcomes were followed up over two years. Patients in the MPT group had shorter fever after retreatment and lower medical costs; more rapid declines in C-reactive protein (CRP), neutrophils (N%), and platelet (PLT) levels; and more rapid rise in sodium. However, they also probably had a higher incidence of treatment failure and CALs than the additional IVIG treatment group in the long-term follow-up. Caution is still required in the use of MPT to treat IVIG-resistant KD.
- Open Access
- 10 March 2020
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2020, 1-6
Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
Children with Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) have a higher incidence of coronary artery lesions (CAL). Despite the association between Purinergic receptor P2Y12 (P2RY12) polymorphism, KD genetic susceptibility, and CAL complications being proved, few studies have assessed the relationship between P2RY12 polymorphisms and IVIG resistance in patients with KD. We recruited 148 KD patients with IVIG resistance and 611 with IVIG sensitivity and selected five P2RY12 polymorphisms: rs9859538, rs1491974, rs7637803, rs6809699, and rs2046934. A significant difference in the genotype distributions between patients was only observed for the rs6809699 A > C polymorphism (AC vs. AA: adjusted odds ratio (OR) = 0.48, 95% confidence interval (CI) = 0.27–0.84, ; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27–0.83, ). After adjusting for age and gender, the carriers of the rs6809699 C allele had OR of 0.44 to 0.49 for IVIG sensitivity (AC vs. AA: adjusted OR = 0.48, 95% confidence interval (CI) = 0.27–0.84, ; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27–0.83, ) compared to the carriers of a rs6809699 AA genotype, suggesting the protective effect of this SNP against IVIG resistance. Moreover, individuals with all five protective polymorphisms experienced a significantly decreased IVIG resistance compared to that of individuals with up to three protective polymorphisms (adjusted OR = 0.27, 95% CI = 0.13–0.57, ). Our results suggest that the P2RY12 rs6809699 polymorphism could be used as a biomarker to predict IVIG resistance in KD patients.- 10 March 2020
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2020, 1-6
Open AccessAssociation between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
Children with Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) have a higher incidence of coronary artery lesions (CAL). Despite the association between Purinergic receptor P2Y12 (P2RY12) polymorphism, KD genetic susceptibility, and CAL complications being proved, few studies have assessed the relationship between P2RY12 polymorphisms and IVIG resistance in patients with KD. We recruited 148 KD patients with IVIG resistance and 611 with IVIG sensitivity and selected five P2RY12 polymorphisms: rs9859538, rs1491974, rs7637803, rs6809699, and rs2046934. A significant difference in the genotype distributions between patients was only observed for the rs6809699 A > C polymorphism (AC vs. AA: adjusted odds ratio (OR) = 0.48, 95% confidence interval (CI) = 0.27–0.84, ; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27–0.83, ). After adjusting for age and gender, the carriers of the rs6809699 C allele had OR of 0.44 to 0.49 for IVIG sensitivity (AC vs. AA: adjusted OR = 0.48, 95% confidence interval (CI) = 0.27–0.84, ; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27–0.83, ) compared to the carriers of a rs6809699 AA genotype, suggesting the protective effect of this SNP against IVIG resistance. Moreover, individuals with all five protective polymorphisms experienced a significantly decreased IVIG resistance compared to that of individuals with up to three protective polymorphisms (adjusted OR = 0.27, 95% CI = 0.13–0.57, ). Our results suggest that the P2RY12 rs6809699 polymorphism could be used as a biomarker to predict IVIG resistance in KD patients. - Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 6539398
Distinguishing Kawasaki Disease from Febrile Infectious Disease Using Gene Pair Signatures
Kawasaki disease (KD) is an acute systemic vasculitis of childhood with prolonged fever, and the diagnosis of KD is mainly based on clinical criteria, which is prone to misdiagnosis with other febrile infectious (FI) diseases. Currently, there remain no effective molecular markers for KD diagnosis. In this study, we aimed to use a relative‐expression‐based method k‐TSP and resampling framework to identify robust gene pair signatures to distinguish KD from bacterial and virus febrile infectious diseases. Our study pool consisted of 808 childhood patients from several studies and assigned to three groups, namely, the discovery set (n = 224), validation set‐1 (n = 197), and validation set‐2 (n = 387). We had identified 60 biologically relevant gene pairs and developed a top‐ranked gene pair classifier (TRGP) using the first seven signatures, with the area under the receiver‐operating characteristic curves (AUROC) of 0.947 (95% CI, 0.918‐0.976), a sensitivity of 0.936 (95% CI, 0.872‐0.987), and a specificity of 0.774 (95% CI, 0.705‐0.836) in the discovery set. In the validation set‐1, the TRGP classifier distinguished KD from FI with AUROC of 0.955 (95% CI, 0.919‐0.991), a sensitivity of 0.959 (95% CI, 0.925‐0.986), and a specificity of 0.863 (95% CI, 0.764‐0.961). In the validation set‐2, the predictive performance of classification was with an AUROC of 0.796 (95% CI, 0.747‐0.845), a sensitivity of 0.797 (95% CI, 0.720‐0.864), and a specificity of 0.661 (95% CI, 0.606‐0.717). Our study reveals that gene pair signatures are robust across diverse studies and can be utilized as objective biomarkers to distinguish KD from FI, helping to develop a fast, simple, and effective molecular approach to improve the diagnosis of KD.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 6539398
Open AccessDistinguishing Kawasaki Disease from Febrile Infectious Disease Using Gene Pair Signatures
Kawasaki disease (KD) is an acute systemic vasculitis of childhood with prolonged fever, and the diagnosis of KD is mainly based on clinical criteria, which is prone to misdiagnosis with other febrile infectious (FI) diseases. Currently, there remain no effective molecular markers for KD diagnosis. In this study, we aimed to use a relative‐expression‐based method k‐TSP and resampling framework to identify robust gene pair signatures to distinguish KD from bacterial and virus febrile infectious diseases. Our study pool consisted of 808 childhood patients from several studies and assigned to three groups, namely, the discovery set (n = 224), validation set‐1 (n = 197), and validation set‐2 (n = 387). We had identified 60 biologically relevant gene pairs and developed a top‐ranked gene pair classifier (TRGP) using the first seven signatures, with the area under the receiver‐operating characteristic curves (AUROC) of 0.947 (95% CI, 0.918‐0.976), a sensitivity of 0.936 (95% CI, 0.872‐0.987), and a specificity of 0.774 (95% CI, 0.705‐0.836) in the discovery set. In the validation set‐1, the TRGP classifier distinguished KD from FI with AUROC of 0.955 (95% CI, 0.919‐0.991), a sensitivity of 0.959 (95% CI, 0.925‐0.986), and a specificity of 0.863 (95% CI, 0.764‐0.961). In the validation set‐2, the predictive performance of classification was with an AUROC of 0.796 (95% CI, 0.747‐0.845), a sensitivity of 0.797 (95% CI, 0.720‐0.864), and a specificity of 0.661 (95% CI, 0.606‐0.717). Our study reveals that gene pair signatures are robust across diverse studies and can be utilized as objective biomarkers to distinguish KD from FI, helping to develop a fast, simple, and effective molecular approach to improve the diagnosis of KD.
- 6 February 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 891-900
Serum exosomal microRNA let‐7i‐3p as candidate diagnostic biomarker for Kawasaki disease patients with coronary artery aneurysm
Kawasaki disease (KD) is a systemic vasculitis syndrome that leads to coronary artery aneurysm (CAA). While echocardiography is the most important imaging modality for coronary artery assessment, a specific diagnostic biomarker complementary for CAA has not been reported. We aimed to analyze the profiles of exosomal miRNAs extracted from the serum of KD patients and controls to identify candidate biomarkers for CAA. Serum samples from 39 healthy children, 42 CAA patients, 38 coronary artery dilatation (CAD) patients and 45 virus‐infected patients including 24 EBV patients and 21 ADV patients were randomly selected. Next generation sequencing was used to analyze serum exosomal miRNA to detect differentially expressed miRNAs. Biomarker candidates were validated by qRT‐PCR. One hundred (and) ninety‐six differentially expressed miRNAs (DEMs) were detected in CAA patients and healthy children. There were 70 DEMs and 140 DEMs in CAA patients versus CAD patients, and in CAA patients versus virus‐infected patients, respectively. We selected the three most upregulated (let‐7i‐3p, miR‐17‐3p, and miR‐210‐5p) and the three most downregulated miRNAs (miR‐6743‐5p, miR‐1246, and miR‐6834‐5p) in the DEMs, which were expressed differentially in CAA patients versus healthy children, and in CAA patients versus virus‐infected patients, not in virus‐infected patients versus healthy children, as biomarker candidates. Excluded DEMs of CAD and virus‐infected patients, let‐7i‐3p was detected by sequence data analysis as a biomarker candidate for CAA patients, and then validated by qRT‐PCR in a larger set of clinical samples. As a biomarker candidate, let‐7i‐3p provides an additional means of diagnosing CAA patients. Additionally, miRNA biomarkers complement ultrasonic imaging, allowing for greater diagnostic precision. © 2019 IUBMB Life, 2019
- 6 February 2019
- Published by Wiley in IUBMB Life
- Vol. 71 (7) , 891-900
Serum exosomal microRNA let‐7i‐3p as candidate diagnostic biomarker for Kawasaki disease patients with coronary artery aneurysm
Kawasaki disease (KD) is a systemic vasculitis syndrome that leads to coronary artery aneurysm (CAA). While echocardiography is the most important imaging modality for coronary artery assessment, a specific diagnostic biomarker complementary for CAA has not been reported. We aimed to analyze the profiles of exosomal miRNAs extracted from the serum of KD patients and controls to identify candidate biomarkers for CAA. Serum samples from 39 healthy children, 42 CAA patients, 38 coronary artery dilatation (CAD) patients and 45 virus‐infected patients including 24 EBV patients and 21 ADV patients were randomly selected. Next generation sequencing was used to analyze serum exosomal miRNA to detect differentially expressed miRNAs. Biomarker candidates were validated by qRT‐PCR. One hundred (and) ninety‐six differentially expressed miRNAs (DEMs) were detected in CAA patients and healthy children. There were 70 DEMs and 140 DEMs in CAA patients versus CAD patients, and in CAA patients versus virus‐infected patients, respectively. We selected the three most upregulated (let‐7i‐3p, miR‐17‐3p, and miR‐210‐5p) and the three most downregulated miRNAs (miR‐6743‐5p, miR‐1246, and miR‐6834‐5p) in the DEMs, which were expressed differentially in CAA patients versus healthy children, and in CAA patients versus virus‐infected patients, not in virus‐infected patients versus healthy children, as biomarker candidates. Excluded DEMs of CAD and virus‐infected patients, let‐7i‐3p was detected by sequence data analysis as a biomarker candidate for CAA patients, and then validated by qRT‐PCR in a larger set of clinical samples. As a biomarker candidate, let‐7i‐3p provides an additional means of diagnosing CAA patients. Additionally, miRNA biomarkers complement ultrasonic imaging, allowing for greater diagnostic precision. © 2019 IUBMB Life, 2019
- 16 December 2013
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 11 (5) , 586-593
Synthesis and Antitumor Activities of α-,γ-mangostin Derivatives
The α-Mangostin and -Mangostin were mainly isolated from Garcinia Mangostana L. as representative Xanthone's natural products of plant origin, revealed high activity of antitumor, antioxidation and other diverse pharmacological activities. A series of α, γ-Mangostin derivatives LT-1~17 has been synthesized, and confirmed by 1H NMR, 13C NMR, MS(supplement file). Compounds LT-2~17, as novel Xanthone, have been reported for the first time. Their antitumor activities have been investigated by MTT method in cell lines: A549, K562, CNE, KB-3-1, MCF-7 and HepG2. A number of compounds showed potent anti-tumor activity, in some cases even higher (more effective) than Mangostins. Compound 3 with an IC50 value of 1.73 µM in the A549 cell line, which was two-fold, acted more active than ADM (adriamycin) and α, γ-Mangostin, and had the most potent anti-tumor activity (IC50=2.15 µM) for the MCF-7 cell line in all synthetic derivatives. α, γ-Mangostin and ADM showed potent anti-tumor activity (IC50=2.82 µM) for HepG2 cell line, and less potent anti-tumor activity in other cell lines compared with the compound LT-12. It was obtained by esterification of the C-3, C-7 phenolic-OH of the α-Mangostin with acetyl group resulted the potent anti-tumor acvitity, which indicated that the phenolic-OH of the Mangostins had a great impaction on the anti-tumor activity of Mangostins.
- 16 December 2013
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 11 (5) , 586-593
Synthesis and Antitumor Activities of α-,γ-mangostin Derivatives
The α-Mangostin and -Mangostin were mainly isolated from Garcinia Mangostana L. as representative Xanthone's natural products of plant origin, revealed high activity of antitumor, antioxidation and other diverse pharmacological activities. A series of α, γ-Mangostin derivatives LT-1~17 has been synthesized, and confirmed by 1H NMR, 13C NMR, MS(supplement file). Compounds LT-2~17, as novel Xanthone, have been reported for the first time. Their antitumor activities have been investigated by MTT method in cell lines: A549, K562, CNE, KB-3-1, MCF-7 and HepG2. A number of compounds showed potent anti-tumor activity, in some cases even higher (more effective) than Mangostins. Compound 3 with an IC50 value of 1.73 µM in the A549 cell line, which was two-fold, acted more active than ADM (adriamycin) and α, γ-Mangostin, and had the most potent anti-tumor activity (IC50=2.15 µM) for the MCF-7 cell line in all synthetic derivatives. α, γ-Mangostin and ADM showed potent anti-tumor activity (IC50=2.82 µM) for HepG2 cell line, and less potent anti-tumor activity in other cell lines compared with the compound LT-12. It was obtained by esterification of the C-3, C-7 phenolic-OH of the α-Mangostin with acetyl group resulted the potent anti-tumor acvitity, which indicated that the phenolic-OH of the Mangostins had a great impaction on the anti-tumor activity of Mangostins.